AhmedOKasebMD

Professor with Tenure, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Join to view full profile

Dr. Kaseb is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kaseb's full profile

Already have an account?

Office
1515 Holcombe Boulevard
Unit Number: 426
Houston, TX 77030
Phone+1 713-792-2828

Fax+1 713-563-0541

Summary

Editor-in-Chief, J of HCC. Director, HCC Program

Education & Training

Henry Ford Health/Henry Ford HospitalFellowship, Hematology and Medical Oncology, 2005 - 2007
Wayne State University School of MedicineResidency, Internal Medicine, 2001 - 2004
Cairo University School of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2021 - Present
GA State Medical License 2022 - 2026
TX State Medical License 2007 - 2026
WA State Medical License 2022 - 2026
AZ State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
TN State Medical License 2022 - 2025
AL State Medical License 2023 - 2024
OK State Medical License 2020 - 2024
MI State Medical License 2001 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery Start of enrollment: 2005 Oct 01
Completed
Phase 2
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Start of enrollment: 2007 May 01
Terminated
Phase 2
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy Start of enrollment: 2011 Apr 14
Completed
Phase 2
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Sep 13
Completed
Phase 2
Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer Start of enrollment: 2016 Dec 09
Completed
Phase 2
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Start of enrollment: 2017 Sep 28
Completed
Phase 2
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer Start of enrollment: 2021 Jul 28
Recruiting
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer Start of enrollment: 2021 Feb 10
Recruiting
Phase 2
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma Start of enrollment: 2019 Aug 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

3498 citations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux
The New England Journal of Medicine. 2020-05-13
669 citations
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere, Matthias Pinter
Nature. 2021-04-15
272 citations
Biliary cancer: Utility of next-generation sequencing for clinical management.
Milind Javle, Tanios Bekaii-Saab, Apurva Jain, Ying Wang, Robin Katie Kelley
Cancer. 2016-12-15

Journal Articles

Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study
Felipe Samaniego, Boris Blechacz, Ahmed Kaseb, Bruno P Granwehr, Aung Naing, Issam I Raad, Ethan Miller, Harrys A Torres, Nature

Lectures

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

What’s New in Treating Hepatocellular Carcinoma, the Most Common Liver Cancer?April 14th, 2023
Perioperative Opdivo Alone, in Combination with Yervoy Safe in Patients with HCCMarch 18th, 2022
MD Anderson Research Highlights for March 9, 2022March 9th, 2022
Join now to see all